(l)-N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)propenamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (l)-N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)propenamide
• 英文别名: (l)-N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)acrylamide；N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)propenamide；N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)acrylamide；acryl-spermine；N-[3-[4-(3-aminopropylamino)butylamino]propyl]prop-2-enamide
• 化学式: C₁₃H₂₈N₄O
• 分子量: 256.392
• InChiKey: MYDLCNFGTVXZRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  18
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  79.2
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  精胺 、 丙烯酸 在 N-羟基丁二酰亚胺 作用下， 以 氯仿 为溶剂， 生成 (l)-N-(3-((4-((3-aminopropyl)amino)butyl)amino)propyl)propenamide
  参考文献：
  名称：

  [EN] A NOVEL RNAi MOLECULE DELIVERY PLATFORM BASED ON SINGLE-siRNA AND shRNA NANOCAPSULES
  [FR] PLATEFORME D'ADMINISTRATION DE NOUVELLES MOLÉCULES D'ARNI BASÉES SUR DES NANOCAPSULES DE SIARN UNIQUE ET/OU SHARN

  摘要：

  本文披露了新型siRNA和shRNA纳米胶囊及传递方法。这些siRNA和shRNA纳米胶囊及传递方法具有很高的稳健性和有效性。该发明为RNAi传递提供了一个平台，具有低毒性和长细胞内半衰期，可用于实际治疗应用。

  公开号：

  WO2013138783A1

文献信息

• RNAi molecule delivery platform based on single-siRNA and shRNA nanocapsules
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US10568844B2

  公开（公告）日：2020-02-25

  Novel siRNA and shRNA nanocapsules and delivery methods are disclosed herein. These siRNA and shRNA nanocapsules and delivery methods are highly robust and effective. This invention provides a platform for RNAi delivery with low toxicity and long intracellular half-life for practical therapeutic applications.

  本文公开了新型 siRNA 和 shRNA 纳米胶囊及递送方法。这些 siRNA 和 shRNA 纳米胶囊及递送方法非常坚固有效。本发明为实际治疗应用提供了一个毒性低、细胞内半衰期长的 RNAi 递送平台。
• Single siRNA Nanocapsules for Enhanced RNAi Delivery
  作者：Ming Yan、Min Liang、Jing Wen、Yang Liu、Yunfeng Lu、Irvin S. Y. Chen

  DOI：10.1021/ja304649a

  日期：2012.8.22

  Synthetic siRNA has been considered as a highly promising therapeutic agent for human diseases. However, clinical use of siRNA has been hampered by instability in the body and inability to deliver sufficient RNA interference compounds to the tissues or cells. To address this challenge, we present here a single siRNA nanocapsule delivery technology, which is achieved by encapsulating a single siRNA molecule within a degradable polymer nanocapsule with a diameter around 20 nm and positive surface charge. As proof-of-concept, since CCR5 is considered a major silencing target of HIV therapy, CCR5-siRNA. nanocapsules were delivered into 293T cells and successfully downregulated the CCRS RNA fused with mCherry reporter RNA. In the absence of human serum, nanocapsules and lipofectamine silenced expression of CCR5-mCherry expression to 8% and 15%, respectively. Such nanocapsules maintain the integrity of siRNA inside even after incubation with ribonuclease and serum for 1 h; under the same conditions, siRNA is degraded in the native form or when formulated with lipofectamine. In the presence of serum, CCR5-siRNA nanocapsules knocked down CCR5-mCherry expression to less than 15% while siRNAs delivered through lipofectamine slightly knocked down the expression to 55%. In summary, this work provides a novel platform for siRNA delivery that can be developed for therapeutic purposes.
• NANOCAPSULES FOR THE DELIVERY OF CELL MODULATING AGENTS
  申请人：CSL Behring LLC

  公开号：EP3898978A2

  公开（公告）日：2021-10-27
• Novel RNAi Molecule Delivery Platform Based on Single-siRNA and shRNA Nanocapsules
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20150071999A1

  公开（公告）日：2015-03-12

  Novel siRNA and shRNA nanocapsules and delivery methods are disclosed herein. These siRNA and shRNA nanocapsules and delivery methods are highly robust and effective. This invention provides a platform for RNAi delivery with low toxicity and long intracellular half-life for practical therapeutic applications.
• NOVEL RNAi MOLECULE DELIVERY PLATFORM BASED ON SINGLE-siRNA AND shRNA NANOCAPSULES
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20180036254A1

  公开（公告）日：2018-02-08

  Novel siRNA and shRNA nanocapsules and delivery methods are disclosed herein. These siRNA and shRNA nanocapsules and delivery methods are highly robust and effective. This invention provides a platform for RNAi delivery with low toxicity and long intracellular half-life for practical therapeutic applications.